Role of surgical resection for refractory germ cell tumors

被引:18
作者
Daneshmand, Siamak [1 ]
机构
[1] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Inst Urol, Los Angeles, CA 90033 USA
关键词
Refractory; Germ cell tumor; Late relapse; Growing teratoma syndrome; Malignant transformation; Salvage chemotherapy; Testis cancer; LYMPH-NODE DISSECTION; GROWING TERATOMA SYNDROME; TERM-FOLLOW-UP; TESTICULAR CANCER; RETROPERITONEAL LYMPHADENECTOMY; PATHOLOGICAL FINDINGS; OUTCOME ANALYSIS; SALVAGE SURGERY; RESIDUAL MASSES; LATE RELAPSE;
D O I
10.1016/j.urolonc.2015.03.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This article aims to critically review the current recommendations with regard to the role of surgery following salvage chemotherapy, growing teratoma syndrome, late relapse, as well as malignant transformation. Methods: All the literature published in English and available on Pubmed pertaining to refractory germ cell tumors was reviewed and the relevant articles, as well as our own institutional experience were included in this review. Results: There is universal agreement that patients with non-seminoma who have residual tumor measuring greater than one centimeter should undergo post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for resection of potential teratoma or viable germ cell tumor. The role of surgical resection is less clear in patients who are deemed to have germ cell tumors refractory to chemotherapy. Patients with residual masses following second line therapy, those with growing teratoma, late relapse, and malignant transformation should all be considered for upfront surgical resection. Compared with the typical PC-RPLND, these operations are generally more complex, with a higher proportion requiring adjunctive procedures; and should be performed in experienced, tertiary referral centers. Conclusion: Patients who have complete resection of disease are sill curable and patients with chemorefractory disease should have evaluation by an expert surgeon. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:370 / 378
页数:9
相关论文
共 57 条
[1]   Salvage Chemotherapy With High-Dose Carboplatin and Etoposide With Peripheral Blood Stem Cell Transplant in Patients With Relapsed Pure Seminoma [J].
Agarwala, Anuj K. ;
Perkins, Susan M. ;
Abonour, Rafat ;
Brames, Mary J. ;
Einhorn, Lawrence H. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (03) :286-288
[2]   Thoracoabdominal resection of retrocrural residual cancers [J].
Albers, P ;
Höltl, W ;
Heidenreich, A ;
Aharinejad, S .
AKTUELLE UROLOGIE, 2004, 35 (02) :141-150
[3]   Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers [J].
Albers, P ;
Ganz, A ;
Hannig, E ;
Miersch, MDE ;
Müller, SC .
JOURNAL OF UROLOGY, 2000, 164 (02) :381-384
[4]   The growing teratoma syndrome:: results of therapy and long-term follow-up of 33 patients [J].
André, F ;
Fizazi, K ;
Culine, S ;
Droz, JP ;
Taupin, P ;
Lhommé, C ;
Terrier-Lacombe, MJ ;
Théodore, C .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (11) :1389-1394
[5]   2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial [J].
Bachner, M. ;
Loriot, Y. ;
Gross-Goupil, M. ;
Zucali, P. A. ;
Horwich, A. ;
Germa-Lluch, J. -R. ;
Kollmannsberger, C. ;
Stoiber, F. ;
Flechon, A. ;
Oechsle, K. ;
Gillessen, S. ;
Oldenburg, J. ;
Cohn-Cedermark, G. ;
Daugaard, G. ;
Morelli, F. ;
Sella, A. ;
Harland, S. ;
Kerst, M. ;
Gampe, J. ;
Dittrich, C. ;
Fizazi, K. ;
De Santis, M. .
ANNALS OF ONCOLOGY, 2012, 23 (01) :59-64
[6]   LATE RELAPSE OF TESTICULAR CANCER [J].
BANIEL, J ;
FOSTER, RS ;
GONIN, R ;
MESSEMER, JE ;
DONOHUE, JP ;
EINHORN, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1170-1176
[7]   Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer [J].
Beck, SDW ;
Foster, RS ;
Bihrle, R ;
Einhorn, LH ;
Donohue, JP .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2005, 23 (06) :423-430
[8]   Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection [J].
Beck, SDW ;
Foster, RS ;
Bihrle, R ;
Einhorn, LH ;
Donohue, JP .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6149-6156
[9]   Post chemotherapy RPLND in patients with elevated markers: Current concepts and clinical outcome [J].
Beck, Stephen D. W. ;
Foster, Richard S. ;
Bihrle, Richard ;
Einhorn, Lawrence H. ;
Donohue, John P. .
UROLOGIC CLINICS OF NORTH AMERICA, 2007, 34 (02) :219-+
[10]   Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone [J].
Coogan, CL ;
Foster, RS ;
Rowland, RG ;
Bihrle, R ;
Smith, ER ;
Einhorn, LH ;
Roth, BJ ;
Donohue, JP .
UROLOGY, 1997, 50 (06) :957-962